90 completed, 54 recruiting, 39 unknown, 18 terminated. 59 Phase 2, 37 Phase 3, 36 Phase 1, 32 Not applicable, 14 Phase 4.
Follow Optic Neuritis: new trials by email Literature Review of Optic Neuritis trials Research Report on Optic Neuritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle | Phase 2 | Withdrawn | Michael, Levy M.D.,Ph.D. | 2026-12-31 | 2025-07-16 | |
| Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder Anti-BAFFR CART - Neuromyelitis Optica Spectrum Disorder | Phase 1 / Phase 2 | Not yet recruiting | Tianjin Medical University General Hospital | 20 | 2026-12-01 | 2026-10-16 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease CTX112 - Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica | Phase 1 / Phase 2 | Not yet recruiting | CRISPR Therapeutics | 220 | 2026-11-01 | 2026-10-22 |
| Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy UPLIZNA - Neuromyelitis Optica Spectrum Disorder, Pregnancy Related | Recruiting | Amgen | 60 | 2026-10-15 | 2026-08-31 | |
| Early Prediction of Outcomes Following Optic Neuritis: Development and Acceptability of a Prognostic Tool No Intervention: Observational Cohort - Optic Neuritis, Multiple Sclerosis | Not yet recruiting | King's College London | 180 | 2026-09-01 | 2026-07-15 | |
| Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder Placebo, IL-2 (interleukin 2) - Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 60 | 2026-08-30 | 2026-09-09 |
| Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) Ravulizumab - NMOSD, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 19 | 2026-07-20 | 2026-09-11 |
| A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD Satralizumab - Neuromyelitis Optica Spectrum Disorders (NMOSD) | Recruiting | Junwei Hao, MD | 50 | 2026-07-20 | 2026-08-13 | |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG) | Phase 1 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 18 | 2026-07-01 | 2026-06-30 |
| Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial Crisugabalin, Placebo+Crisugabalin - Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain | Phase 4 | Not yet recruiting | Tang-Du Hospital | 110 | 2026-06-15 | 2026-07-13 |
| Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research Privosegtor, Methylprednisolone, Placebo - Optic Neuritis | Phase 3 | Recruiting | Oculis | 210 | 2026-05-28 | 2026-08-14 |
| The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder. KSVCBD injection - Neuromyelitis Optica Spectrum Disease (NMOSD) | Early Phase 1 | Not yet recruiting | Chinese PLA General Hospital | 18 | 2026-05-15 | 2026-05-18 |
| A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) Satralizumab - Neuromyelitis Optica Spectrum Disorder, NMOSD | Phase 3 | Recruiting | Hoffmann-La Roche | 8 | 2026-05-06 | 2026-10-01 |
| Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Apparently Stable Patients MRI, Immunological Factors - Neuromyelitis Optica Spectrum Disorders | Not yet recruiting | IRCCS San Raffaele | 50 | 2026-04-01 | 2026-04-13 | |
| Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 1 | Recruiting | Tongji Hospital | 6 | 2026-04-01 | 2026-05-12 |
| Tongji NADs Cohort No active interventions - Multiple Sclerosis, NMO Spectrum Disorder | Not yet recruiting | Tongji Hospital | 1550 | 2026-03-01 | 2026-01-21 | |
| Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases QT-019C - Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis | Early Phase 1 | Not yet recruiting | Tianjin Huanhu Hospital | 15 | 2026-03-01 | 2026-02-11 |
| A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 1 | Not yet recruiting | Huashan Hospital | 15 | 2026-02-01 | 2026-01-15 |
| Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study Eculizumab+IVMP, IVIG+IVMP, IVMP - Neuromyelitis Optica Spectrum Disorder Attack | Phase 4 | Recruiting | Chinese PLA General Hospital | 200 | 2026-02-01 | 2026-03-12 |
| Multiple Sclerosis Versus Neuromyelitis Optica Spectrum Disorder MS (Multiple Sclerosis), NMO Spectrum Disorder (NMOSD) | Not yet recruiting | Assiut University | 100 | 2026-01-01 | 2025-12-26 |
Showing 20 of 241. Sign in to see all of them.
Neuromyelitis Optica (171) · Multiple Sclerosis (88) · Demyelinating Diseases (18) · Myasthenia Gravis (17) · Myelitis, Transverse (17) · Autoimmune Diseases of the Nervous System (16) · Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (16) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (11) · Encephalomyelitis, Acute Disseminated (9) · Optic Nerve Diseases (9) · Autoimmune Diseases (8) · Multiple Sclerosis, Relapsing-Remitting (8) · Multiple Sclerosis, Chronic Progressive (7) · Recurrence (7)
Cranial Nerve Diseases (241) · Eye Diseases (238) · Nervous System Diseases (237) · Optic Nerve Diseases (232) · Immune System Diseases (210) · Demyelinating Autoimmune Diseases, CNS (206) · Autoimmune Diseases (203) · Autoimmune Diseases of the Nervous System (194) · Demyelinating Diseases (194) · Myelitis, Transverse (156) · Pathological Conditions, Signs and Symptoms (51) · Pathologic Processes (41) · Disease Attributes (37) · Neurodegenerative Diseases (37)
Methylprednisolone (11) · inebilizumab (8) · Rituximab (7) · eculizumab (7) · satralizumab (7) · Adrenal Cortex Hormones (6) · Azathioprine (6) · Cyclophosphamide (5) · Prednisone (5) · ravulizumab (5) · Immunoglobulins, Intravenous (4) · Mycophenolic Acid (4) · Plasma Exchange (4) · 4-Aminopyridine (3) · Antilymphocyte Serum (3)
Tianjin Medical University General Hospital (14) · Alexion Pharmaceuticals, Inc. (9) · Fondation Ophtalmologique Adolphe de Rothschild (7) · Tongji Hospital (7) · Chinese PLA General Hospital (6) · Hoffmann-La Roche (5) · Hospices Civils de Lyon (5) · Third Affiliated Hospital, Sun Yat-Sen University (5) · Xuanwu Hospital, Beijing (5) · Beijing Tiantan Hospital (4) · First Affiliated Hospital of Guangxi Medical University (4) · Johns Hopkins University (4) · Mayo Clinic (4) · Tang-Du Hospital (4) · Amgen (3)
China (76) · United States (71) · France (36) · United Kingdom (21) · Germany (20) · Italy (19) · Canada (18) · Spain (15) · South Korea (13) · Japan (11) · Poland (10) · Australia (9) · Turkey (Türkiye) (9) · Czechia (7) · Denmark (7)
Michael Levy, MD, PhD (7) · Fu-Dong Shi, MD,PhD (4) · Junwei Hao, MD (3) · Wei Wang, MD (3) · Chao Quan, Doctor (2) · Dai-shi Tian, MD (2) · Huanfen Zhou, PhD (2) · Jagannadha Avasarala, MD PhD (2) · Jeffrey Weiss, MD (2) · Jinzhou Feng, Ph.D (2) · Quangang Xu, PhD (2) · Richard Burt, MD (2)
PMID 40743487, PMID 26199618, PMID 26604914, PMID 27857759, PMID 27904503, PMID 33676197, PMID 34498507, PMID 36007339, PMID 36724181, PMID 40288333, PMID 16638802, PMID 16831964, PMID 19752302, PMID 21921071, PMID 22236384, PMID 22589446, PMID 22742888, PMID 22926853, PMID 23568718, PMID 23623397, PMID 23764350, PMID 23892551, PMID 24287594, PMID 24871874, PMID 25063544, PMID 25191939, PMID 25199960, PMID 26009577, PMID 26083135, PMID 26092914, PMID 26109993, PMID 26227005, PMID 26396053, PMID 26553836, PMID 26666258, PMID 26822749, PMID 27706045, PMID 28229892, PMID 28538037, PMID 28639937, PMID 28831548, PMID 29172994, PMID 29270420, PMID 29275977, PMID 29507942, PMID 29686116, PMID 29808469, PMID 30050918, PMID 30095536, PMID 30258442
2019 (4), 2014 (2), 2023 (2), 2008 (1), 2015 (1), 2017 (1)